Clinical Trials Directory

Trials / Completed

CompletedNCT02708199

Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic

Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases in Myanmar Artemisinin Resistance Containment Zones and Malaria Antibody Kinetic Analysis

Status
Completed
Phase
Study type
Observational
Enrollment
1,179 (actual)
Sponsor
Department of Medical Research, Lower Myanmar · Academic / Other
Sex
All
Age
6 Years
Healthy volunteers
Accepted

Summary

Detection of the drug resistance molecular markers for falciparum and vivax in Longitudinal follow-up samples collected in Shwegyin Township, Bago Region that is Artemisinin Resistance Containment Tier I.

Detailed description

This study is longitudinal and observational cohort study to detect the drug resistance molecular markers in asymptomatic malaria infected local residents in study site. Only local residence who are not migrants, are recruited in the study and active and passive surveillance have been carried out within one year observation period. At the time of enrollment, blood film examination, rapid diagnosis test (RDT) testing have been done all together with the collection of the venous blood (about 1-2 mL) that would be used for molecular analysis later. All of the RDT or microscopy positive cases were treated according to the National Malaria Treatment Policy in Myanmar. A total of at least 1000 participants have been recruited in the study. Active case detection has been done in every three months. The venous blood were used for molecular based detection of the asymptomatic malaria infection by using High-throughout pooling strategy. All of the positive samples, (falciparum and vivax), have been checked for drug resistance molecular analaysis compared with the previously collected symptomatic malaria infection cases in the same region.

Conditions

Timeline

Start date
2015-01-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2016-03-15
Last updated
2016-03-15

Source: ClinicalTrials.gov record NCT02708199. Inclusion in this directory is not an endorsement.